KOO - I’m only saying that major s/h venture capital, primary endpoint result notwithstanding, has been de-risked post topline BoM vs. pre-topline now that the science has been proved and that continued drug development through some kind of partnering arrangement or an outright buyout is now virtually assured.  In other words, nobody is walking away from this given the results BoM has delivered so far, other than perhaps some impatient retail investors.

I expect (hope) DM will provide more clarity on Friday morning.  We’ll see.